| Catalog No. |
TD-HY546016 |
| Species reactivity |
Human |
| Applications |
Research Grade Biosimilar |
| Host species |
Humanized |
| Isotype |
IgG1-kappa |
| Expression system |
Mammalian Cells |
| Clonality |
Monoclonal |
| Target |
Meconium antigen 100, CEACAM5, CEA, CD66e, Carcinoembryonic antigen-related cell adhesion molecule 5, Carcinoembryonic antigen |
| Endotoxin level |
Please contact the lab for this information. |
| Purity |
>95% purity as determined by SDS-PAGE. |
| Purification |
Protein A/G, purified from cell culture supernatant. |
| Accession |
P06731 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS,pH7.4. |
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Alternate Names |
hMN14,IMMU-130,hMN-14-SN-38,hMN-14-SN-38ADC,hMN14-CL-SN-38,LabetuzumabGovitecan,CAS:219649-07-7 |
| Background |
Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy. |
| Note |
For research use only. Not for use in clinical or therapeutic applications. |